Immunotherapy

Patients with diffuse large B-cell lymphoma (DLBCL) that did not respond to treatment or that came back after two previous treatments had few remaining options — until now.

In 2006, Shinya Yamanaka, a Japanese stem cell researcher, made a groundbreaking discovery that would win him the Nobel Prize. Yamanaka discovered a new way to turn adult, dividing cells into pluripotent stem cells.

“For me, it’s kind of a miracle. I have the second chance in life that I never thought I’d have.”

Dr. Lee says hopes are high for the success of immunotherapies targeting multiple myeloma: “I think we’re seeing a major change in the way we take care of the disease.”
What can be done when cancer is able to hide from your immune system or block the immune response, or if it just isn’t strong enough to kill all the cancer cells?

Dr. Odunsi and his colleagues observed that the tumors of some patients were full of T cells that had managed to work their way inside the tumor. When there were many of these T cells, the patients tended to live longer.

A combination of two immunotherapy drugs shows promise in treating patients with skin cancer that has spread to the brain, according to a study published this week the New England Journal of Medicine.

Not all patients respond to all types of immunotherapies. So how can doctors identify which treatments have the best chance of working in a specific patient? How can they quickly zero in on the best options on a list of immunotherapies that grows longer every day?

Roswell Park Comprehensive Cancer Center researchers have made another step toward personalizing cancer treatment while reducing the toxicity of certain cancer drugs using simple, noninvasive blood tests.

We’re entering a hopeful new era with the development of immunotherapies, which use the power of your own immune system to fight cancer. Here's an introduction to one type, called CAR T-cell therapy.
Results from the CheckMate 214 clinical trial show that combined therapy with two immunotherapy drugs, nivolumab and ipilimumab, can be very effective in the treatment of renal cell carcinoma, the most common type of kidney cancer.
A new clinical trial open at Roswell Park Comprehensive Cancer Center is currently investigating whether beta blockers, which calm the body’s response to stress, can boost immunotherapy in patients with advanced melanoma.